Navigation Links
Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon
Date:10/30/2010

BI 207127 for 5-days monotherapy.
(Poster 1862. L. Lagace, et al. Tue, November 2 - 7:00 AM. Hynes: Exhibit Hall C)


  • The Liver Kp Corrected Inhibitory Quotient (LCIQ): A pharmacokinetic-pharmacodynamic model for direct-acting HCV antivirals
    (Poster 1866. J. Duan, et al. Tue, November 2 – 7:00 AM. Hynes: Exhibit Hall C)About Hepatitis C Virus (HCV)HCV is an infectious disease of the liver and is a leading cause of chronic liver disease and liver transplant. The number of individuals chronically infected with HCV globally has been estimated at 170 million, with 3–4 million new infections occurring each year. Only about 20–45% of patients clear the virus in the acute phase. Of the remaining chronically infected patients, 20% will develop cirrhosis within a mean of 20 years. The mortality rate after cirrhosis has developed is 2-5% per year. End-stage liver disease due to HCV infection currently represents the major indication for liver transplantation in the Western world.

    About Boehringer Ingelheim in VirologyBoehringer Ingelheim has more than 6,900 scientists working in cross disciplinary teams within our global R&D network in six large therapeutic areas, including virology. In addition to its ongoing research program for HCV, Boehringer Ingelheim has a long-standing history in virology drug development, including compounds for the treatment of HIV. The company has a well established research center in Laval, Canada, dedicated to virology research since the early 1990's, and is committed to developing new therapies for virological diseases with a high unmet medical need.

    Boehringer Ingelheim in Hepatitis C Virus (HCV)BI 201335 is an investigational oral HCV NS3/4A protease inhibitor, discovered from Boehringer Ingelheim's own research and development, which has completed clinical trials through Phase IIb (SILEN-C studies). This Phase II program supports the investigation of BI 201335 in
    '/>"/>


  • SOURCE Boehringer Ingelheim Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
    3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
    4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    5. Tapestry Reports Second Quarter 2007 Results
    6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
    8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
    9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
    10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
    11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... , Oct. 22, 2014   Reproductive Medicine ... leader in the field of infertility, presents new ... embryonic screening. The research abstract, released during the ... Medicine (ASRM) meeting in Honolulu, Hawaii ... single gene defect (SGD) pre-implantation genetic diagnosis (PGD). ...
    (Date:10/22/2014)... -- AVACEN Medical announced today that its AVACEN 100 ... by the U.S. Food and Drug Administration. This clearance ... Internet for: the temporary relief of joint pain ... sprains . Logo - http://photos.prnewswire.com/prnh/20141021/153513 ... a sophisticated medical device incorporating over 3,000 firmware instructions ...
    (Date:10/22/2014)... 2014  With a vision to ensure safety ... Global Pharmaceutical and Biotech manufacturer selects and implements ... solution to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... aggregated by the Xyntek and Antares solution is ...
    Breaking Medicine Technology:New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
    ... A Commonwealth Fund case study notes that ... aligned "to launch innovations and organize services in ways that make ... study -- along other profiles looking at medical systems that have ... high performing health care system -- has been in the works ...
    ... Conatus Pharmaceuticals Inc. announced today the initiation of a ... for the treatment of liver disease associated with Hepatitis C ... treatment with approved standard of care treatments is not currently ... patients who failed standard of care treatment are expected to ...
    Cached Medicine Technology:Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative 2Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative 3Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis 2
    (Date:10/22/2014)... October 22, 2014 Akeso Biomedical, ... for the treatment of bacterial infections, microbial biofilms, and ... joined its board of directors. , Dr. ... Systems at The Massachusetts Institute of Technology, or MIT. ... since 1968. Dr. Sinskey also holds positions as Co-Director ...
    (Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... are only about half as likely as white women to ... indicates, and the racial disparity persists even when donor eggs ... white patients became pregnant after IVF, compared to about 17 ... cycles over two years to tease out the impact of ...
    (Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... to increased blood pressure, according to a new study. ... pressure for young adult women or for teenagers, according to ... or moderately, their risk of high blood pressure was cut ... in older adult men and women," said lead researcher Dr. ...
    (Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
    (Date:10/22/2014)... Thompson HealthDay Reporter TUESDAY, Oct. ... with Ebola while working for NBC News in Liberia ... special isolation unit at Nebraska Medical Center in Omaha, where he ... Tuesday. A blood test confirmed by the U.S. Centers for ... home to Providence, R.I., NBC News reported Tuesday night. ...
    Breaking Medicine News(10 mins):Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
    ... ... were also desperate pioneers whose drug use had gotten the better of them ... test whether an epilepsy drug could reduce their use of cocaine. In the ... spent the final three weeks of the study with no signs of cocaine ...
    ... Urges U.S. Senate to Support and Pass Landmark Health Care ... U.S. House of Representatives, historic vote on health care reform ... system - but for millions of Americans struggling with soaring ... and pass the Affordable Health Care for America Act (H.R. ...
    ... , WASHINGTON, Nov. 11 An article running in ... American Medical Association , "Silent Epidemic of Viral Hepatitis ... the urgent need for Congress to act on new ... a comprehensive prevention, research, and medical management referral program ...
    ... ROCHESTER, N.Y., Nov. 11 The University of Rochester ... center that will assist researchers studying the electrical activity ... safety, understanding cardiac arrhythmias, and developing new electrocardiograph technologies. ... -- funded by a $2.3 million grant from the ...
    ... Association,s House of Delegates elected Paula Anderson, RNC to the ... Anderson succeeds Barbara A. Nash MS, RN, C, CNS, who ... ONA. , Anderson is a Staff Nurse at The ... been a bedside Registered Nurse for almost 40 years. She ...
    ... This holiday season, Ingenious Med is partnering with Children,s Restoration ... 2,000 Metro-Atlanta children living in group homes and shelters. ... an effort to stock 129 shelters with basic needs as ... Ingenious Med to host these food drives throughout Atlanta. ...
    Cached Medicine News:Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 2Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 3Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 4Health News:House Health Reform Plan Will Benefit Millions of Illinoisans 2Health News:NVHR: New JAMA Article Underscores Urgent Need for Congress to Act on Viral Hepatitis Detection, Management Funding 2Health News:New Research Center to Focus on Cardiac Safety and Innovation 2Health News:New Research Center to Focus on Cardiac Safety and Innovation 3Health News:Ohio Nurses Association Announces New President; 2009-2011 Board of Directors 2Health News:Ingenious Med Partners with Children's Restoration Network for Holiday Charity 2
    ... Propel Cannulated Interference Screw ... unbiased, symmetrical starts, while limiting ... distal end reduces abrasion where ... unequalled protection. Aggressive-pitch thread enables ...
    Cannulated Interference Screws...
    Cannulated Interference Screws...
    ... CoEase is designed to provide excellent protection ... unique advantage of being closer to an ... This allows CoEase to maintain viscosity ... best of both worlds for superb performance ...
    Medicine Products: